← Mechanisms of action
Melanoma cells
CELL-LINEHomo sapiens
Drugs acting on this target (11)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| talimogene laherparepvec (Imlygic) | Disrupting agent | approved | Biological | Melanoma cells disrupting agent |
| 1650-g vaccine | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| advtmm2/dc vaccine | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| alvac melanoma multi-antigen therapeutic vaccine | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| canarypox-hil-12 melanoma vaccine | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| cyt004-melqbg10 | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| grn-1201 | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| melanoma vaccine modified to express hla a2/4-1bb ligand | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| melcancervac | Immunity, active | experimental | Cell therapy | immunity, active - melanoma cells |
| na17.a2 peptide | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |
| pol-103a | Immunity, active | experimental | Vaccine | immunity, active - melanoma cells |